FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4238417967> ?p ?o ?g. }

• W4238417967 endingPage "91" @default.
• W4238417967 startingPage "91" @default.
• W4238417967 abstract "Abstract Abstract 91 In normal and leukemic hemopoiesis, stem cells differentiate through intermediate progenitors into terminal cells. In human Acute Myeloid Leukemia (AML), there is uncertainty about: (i) whether there is more than one leukemic stem cell (LSC) population in any one individual patient; (ii) how homogeneous AML LSCs populations are at a molecular and cellular level and (iii) the relationship between AML LSCs and normal stem/progenitor populations. Answers to these questions will clarify the molecular pathways important in the stepwise transformation of normal HSCs/progenitors. We have studied 82 primary human CD34+ AML samples (spanning a range of FAB subtypes, cytogenetic categories and FLT3 and NPM1 mutation states) and 8 age-matched control marrow samples. In ∼80% of AML cases, two expanded populations with hemopoietic progenitor immunophenotype coexist in most patients. One population is CD34+CD38-CD90-CD45RA+ (CD38-CD45RA+) and the other CD34+CD38+CD110-CD45RA+ (GMP-like). Both populations from 7/8 patients have leukemic stem cell (LSC) activity in primary and secondary xenograft assays with no LSC activity in CD34- compartment. The two CD34+ LSC populations are hierarchically ordered, with CD38-CD45RA+ LSC giving rise to CD38+CD45RA+ LSC in vivo and in vitro. Limit dilution analysis shows that CD38-CD45RA+LSCs are more potent by 8–10 fold. From 18 patients, we isolated both CD38-CD45RA+ and GMP-like LSC populations. Global mRNA expression profiles of FACS-sorted CD38-CD45RA+ and GMP-like populations from the same patient allowed comparison of the two populations within each patient (negating the effect of genetic/epigenetic changes between patients). Using a paired t-test, 748 genes were differentially expressed between CD38-CD45RA+ and GMP-like LSCs and separated the two populations in most patients in 3D PCA. This was confirmed by independent quantitative measures of difference in gene expression using a non-parametric rank product analysis with a false discovery rate of 0.01. Thus, the two AML LSC populations are molecularly distinct. We then compared LSC profiles with those from 4 different adult marrow normal stem/progenitor cells to identify the normal stem/progenitor cell populations which the two AML LSC populations are most similar to at a molecular level. We first obtained a 2626 gene set by ANOVA, that maximally distinguished normal stem and progenitor populations. Next, the expression profiles of 22 CD38-CD45RA+ and 21 GMP-like AML LSC populations were distributed by 3D PCA using this ANOVA gene set. This showed that AML LSCs were most closely related to their normal counterpart progenitor population and not normal HSC. This data was confirmed quantitatively by a classifier analysis and hierarchical clustering. Taken together, the two LSC populations are hierarchically ordered, molecularly distinct and their gene expression profiles do not map most closely to normal HSCs but rather to their counterpart normal progenitor populations. Finally, as global expression profiles of CD38-CD45RA+ AML LSC resemble normal CD38-CD45RA+ cells, we defined the functional potential of these normal cells. This had not been previously determined. Using colony and limiting dilution liquid culture assays, we showed that single normal CD38-CD45RA+ cells have granulocyte and macrophage (GM), lymphoid (T and B cell) but not megakaryocyte-erythroid (MK-E) potential. Furthermore, gene expression studies on 10 cells showed that CD38-CD45RA+ cells express lymphoid and GM but not Mk-E genes. Taken together, normal CD38-CD45RA+ cells are most similar to mouse lymphoid primed multi-potential progenitor cells (LMPP) cells and distinct from the recently identified human Macrophage Lymphoid progenitor (MLP) population. In summary, for the first time, we show the co-existence of LMPP-like and GMP-like LSCs in CD34+ AML. Thus, CD34+ AML is a progenitor disease where LSCs have acquired abnormal self-renewal potential (Figure 1). Going forward, this work provides a platform for determining pathological LSCs self-renewal and tracking LSCs post treatment, both of which will impact on leukemia biology and therapy. Disclosures: No relevant conflicts of interest to declare." @default.
• W4238417967 created "2022-05-12" @default.
• W4238417967 creator A5002133342 @default.
• W4238417967 creator A5003621086 @default.
• W4238417967 creator A5008779748 @default.
• W4238417967 creator A5010051623 @default.
• W4238417967 creator A5011789285 @default.
• W4238417967 creator A5011949577 @default.
• W4238417967 creator A5023707586 @default.
• W4238417967 creator A5024188669 @default.
• W4238417967 creator A5035853507 @default.
• W4238417967 creator A5038099312 @default.
• W4238417967 creator A5041399698 @default.
• W4238417967 creator A5044175651 @default.
• W4238417967 creator A5052105829 @default.
• W4238417967 creator A5055600777 @default.
• W4238417967 creator A5059661708 @default.
• W4238417967 creator A5071962621 @default.
• W4238417967 creator A5072483286 @default.
• W4238417967 creator A5074400466 @default.
• W4238417967 creator A5074839524 @default.
• W4238417967 creator A5075397421 @default.
• W4238417967 creator A5076984999 @default.
• W4238417967 creator A5079367926 @default.
• W4238417967 creator A5083169786 @default.
• W4238417967 creator A5085324935 @default.
• W4238417967 creator A5086175851 @default.
• W4238417967 creator A5090103959 @default.
• W4238417967 date "2010-11-19" @default.
• W4238417967 modified "2023-10-14" @default.
• W4238417967 title "Co-Existence of LMPP-Like and GMP-Like Leukemia Stem Cells In Acute Myeloid Leukemia" @default.
• W4238417967 doi "https://doi.org/10.1182/blood.v116.21.91.91" @default.
• W4238417967 hasPublicationYear "2010" @default.
• W4238417967 type Work @default.
• W4238417967 citedByCount "0" @default.
• W4238417967 crossrefType "journal-article" @default.
• W4238417967 hasAuthorship W4238417967A5002133342 @default.
• W4238417967 hasAuthorship W4238417967A5003621086 @default.
• W4238417967 hasAuthorship W4238417967A5008779748 @default.
• W4238417967 hasAuthorship W4238417967A5010051623 @default.
• W4238417967 hasAuthorship W4238417967A5011789285 @default.
• W4238417967 hasAuthorship W4238417967A5011949577 @default.
• W4238417967 hasAuthorship W4238417967A5023707586 @default.
• W4238417967 hasAuthorship W4238417967A5024188669 @default.
• W4238417967 hasAuthorship W4238417967A5035853507 @default.
• W4238417967 hasAuthorship W4238417967A5038099312 @default.
• W4238417967 hasAuthorship W4238417967A5041399698 @default.
• W4238417967 hasAuthorship W4238417967A5044175651 @default.
• W4238417967 hasAuthorship W4238417967A5052105829 @default.
• W4238417967 hasAuthorship W4238417967A5055600777 @default.
• W4238417967 hasAuthorship W4238417967A5059661708 @default.
• W4238417967 hasAuthorship W4238417967A5071962621 @default.
• W4238417967 hasAuthorship W4238417967A5072483286 @default.
• W4238417967 hasAuthorship W4238417967A5074400466 @default.
• W4238417967 hasAuthorship W4238417967A5074839524 @default.
• W4238417967 hasAuthorship W4238417967A5075397421 @default.
• W4238417967 hasAuthorship W4238417967A5076984999 @default.
• W4238417967 hasAuthorship W4238417967A5079367926 @default.
• W4238417967 hasAuthorship W4238417967A5083169786 @default.
• W4238417967 hasAuthorship W4238417967A5085324935 @default.
• W4238417967 hasAuthorship W4238417967A5086175851 @default.
• W4238417967 hasAuthorship W4238417967A5090103959 @default.
• W4238417967 hasConcept C10205521 @default.
• W4238417967 hasConcept C109159458 @default.
• W4238417967 hasConcept C153911025 @default.
• W4238417967 hasConcept C159912055 @default.
• W4238417967 hasConcept C196166836 @default.
• W4238417967 hasConcept C201750760 @default.
• W4238417967 hasConcept C203014093 @default.
• W4238417967 hasConcept C2778461978 @default.
• W4238417967 hasConcept C2778729363 @default.
• W4238417967 hasConcept C2779282312 @default.
• W4238417967 hasConcept C28328180 @default.
• W4238417967 hasConcept C2908647359 @default.
• W4238417967 hasConcept C502942594 @default.
• W4238417967 hasConcept C553184892 @default.
• W4238417967 hasConcept C71924100 @default.
• W4238417967 hasConcept C86803240 @default.
• W4238417967 hasConcept C95444343 @default.
• W4238417967 hasConcept C99454951 @default.
• W4238417967 hasConceptScore W4238417967C10205521 @default.
• W4238417967 hasConceptScore W4238417967C109159458 @default.
• W4238417967 hasConceptScore W4238417967C153911025 @default.
• W4238417967 hasConceptScore W4238417967C159912055 @default.
• W4238417967 hasConceptScore W4238417967C196166836 @default.
• W4238417967 hasConceptScore W4238417967C201750760 @default.
• W4238417967 hasConceptScore W4238417967C203014093 @default.
• W4238417967 hasConceptScore W4238417967C2778461978 @default.
• W4238417967 hasConceptScore W4238417967C2778729363 @default.
• W4238417967 hasConceptScore W4238417967C2779282312 @default.
• W4238417967 hasConceptScore W4238417967C28328180 @default.
• W4238417967 hasConceptScore W4238417967C2908647359 @default.
• W4238417967 hasConceptScore W4238417967C502942594 @default.
• W4238417967 hasConceptScore W4238417967C553184892 @default.
• W4238417967 hasConceptScore W4238417967C71924100 @default.
• W4238417967 hasConceptScore W4238417967C86803240 @default.
• W4238417967 hasConceptScore W4238417967C95444343 @default.
• W4238417967 hasConceptScore W4238417967C99454951 @default.

• next